Cytrellis Biosystems, Inc.

Key People

• Dr. Denise Dajles - President and Chief Executive Officer
• Dr. Karyn Siemasko - Vice President of Clinical and Medical Affairs
• Sarah Brice, RN, BSN - Vice President of Commercial Strategy
• Oliver Bennett - Chief Business Officer and General Counsel
• Dr. Shiv Sabesan - Chief Technology Officer

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises seasoned professionals with extensive experience in the medical device and aesthetics industries.

Dr. Denise Dajles, the CEO, has over 20 years of experience in medical device innovation and operations. Other key leaders, such as Dr. Karyn Siemasko and Sarah Brice, bring significant experience in clinical affairs and commercial strategy, respectively. This depth of experience is a strong asset for the company's growth and success.

Clinical Need

Aspect: Very Strong
Summary: The ellacor system addresses a significant unmet need for non-surgical skin rejuvenation.

Traditional methods for skin rejuvenation often involve surgery or thermal energy, which can lead to scarring and longer recovery times. The ellacor system's Micro-Coring technology provides a minimally invasive alternative, effectively removing sagging skin without these drawbacks, thus fulfilling a strong clinical need.

Competition

Aspect: First mover
Summary: Cytrellis is pioneering the Micro-Coring technology in the aesthetic device market.

As the first company to introduce Micro-Coring technology for skin rejuvenation, Cytrellis has the opportunity to establish a strong market presence and brand recognition before competitors enter the space.

Technical Challenge

Aspect: Predictable
Summary: The technology is innovative but based on established medical principles.

While Micro-Coring is a novel application, it leverages known medical techniques, making the technical challenges more manageable and the development process more predictable.

Patent

Aspect: Very Strong
Summary: Cytrellis holds robust patents for its Micro-Coring technology.

The company's proprietary Micro-Coring technology is well-protected by patents, providing a significant barrier to entry for potential competitors and securing the company's market position.

Financing

Aspect: Well-funded
Summary: Cytrellis has secured substantial funding from reputable investors.

With funding from investors like ARCH Venture Partners and D1 Capital Partners, Cytrellis has the necessary resources to advance its product development, expand its market reach, and invest in further innovation.

Regulatory

Aspect: 510k/PMA
Summary: The ellacor system has received FDA clearance and approvals in other markets.

The FDA clearance in 2021 and subsequent approvals in Canada and Saudi Arabia demonstrate the product's compliance with regulatory standards, enabling the company to market its device in multiple regions.

Opportunity Rollup

Odds of Success

4

Peak Market Share

5.35

Segment CAGR

6.3%

Market Segment

Aesthetic Devices

Market Sub Segment

Non-Surgical Skin Rejuvenation

Key Takeaway

Cytrellis Biosystems, with its innovative Micro-Coring technology and strong leadership, is well-positioned to capitalize on the growing demand for non-surgical aesthetic treatments.